7597-67-3

Basic information

• Product Name: methyl 1-benzothiophen-3-ylacetate
• CAS NO: 7597-67-3
• Molecular Formula: C₁₁H₁₀O₂S
• Molecular Weight: 206.2609
• Mol File: 7597-67-3.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 317.8°C at 760 mmHg
• Flash Point: 146°C
• Density: 1.243g/cm³
• Vapor Pressure: 0.000377mmHg at 25°C
• Refractive Index: 1.622
• CAS DataBase Reference: methyl 1-benzothiophen-3-ylacetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 1-benzothiophen-3-ylacetate(7597-67-3)
• EPA Substance Registry System: methyl 1-benzothiophen-3-ylacetate(7597-67-3)

Safety Data

• Hazardous Substances Data: 7597-67-3(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 3216-48-6 2-(benzo[b]thiophen-3-yl)acetonitrile 
• 1131-09-5 benzo[b]thiophene-3-acetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 86738-58-1 N-<2-(3,4-dimethoxyphenyl)ethyl>-3-benzothienylacetamide 
• 1416134-79-6 C₁₇H₁₂O₃S 
• 1416134-91-2 C₁₈H₁₄O₃S 
• 1416134-92-3 C₁₈H₁₄O₄S 
• 1416134-93-4 C₁₉H₁₆O₅S 
• 1416134-80-9 C₁₇H₁₂N₂OS 
• 1416134-97-8 C₁₈H₁₄N₂OS 
• 1416134-98-9 C₁₈H₁₄N₂O₂S 
• 1416134-99-0 C₁₉H₁₆N₂O₃S 
• 87894-73-3 1-phenyl-3H-<1>benzothieno<2,3-c>pyran-3-one 
• 1416134-89-8 C₁₈H₁₂O₂S 
• 1354516-83-8 C₁₈H₁₂O₃S 
• 1354513-57-7 C₁₉H₁₄O₄S 
• 1416134-81-0 C₁₉H₁₆O₃S 

Relevant articles and documents

New Series of Potent Allosteric Inhibitors of Deoxyhypusine Synthase

Deoxyhypusine synthase (DHPS) is the primary enzyme responsible for the hypusine modification and, thereby, activation of the eukaryotic translation initiation factor 5A (eIF5A), which is key in regulating the protein translation processes associated with tumor proliferation. Although DHPS inhibitors could be a promising therapeutic option for treating cancer, only a few studies reported druglike compounds with this inhibition property. Thus, in this work, we designed and synthesized a new chemical series possessing fused ring scaffolds designed from high-throughput screening hit compounds, discovering a 5,6-dihydrothieno[2,3-c]pyridine derivative (26d) with potent inhibitory activity; furthermore, the X-ray crystallographic analysis of the DHPS complex with 26d demonstrated a distinct allosteric binding mode compared to a previously reported inhibitor. These findings could be significantly useful in the functional analysis of conformational changes in DHPS as well as the structure-based design of allosteric inhibitors.

NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING

The present invention relates to novel labelled compounds of formula (I) (C)n-B-(A)m-B-(C)n (I) wherein m is 0 or 1, and n is independently 0, 1, 2 or 3, A, each B and each C are independently selected from phenylene and five- and six-membered heteroaromatic rings, and for a terminal ring B or C also from bicyclic heteroaromatic fused rings having seven to ten ring members, wherein the bond between at least two of the rings A to C may be replaced by a carbonyl group ( -CO- ), wherein at least two of the rings A to C are substituted with one or two groups R, and wherein each ring A to C further optionally is substituted with one or two groups R1, for use in imaging amyloid deposits and aggregated protein in living patients. The invention further relates to imaging methods using labelled or unlabelled compounds of formual I and the use of unlabelled compounds in such methods.

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.